Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.
chemotherapy
endocrine therapy
metastatic breast cancer
patient selection
targeted therapy
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
09
12
2021
revised:
12
01
2022
accepted:
22
01
2022
pubmed:
2
3
2022
medline:
4
5
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation of progression-free survival and, in some cases, also of overall survival. This led to a substantial increase of advanced disease treatability. In the present review we comprehensively and critically describe the most significant progresses in the therapeutic scenario of MBC according to BC subtype. In particular, we reviewed studies reporting practice-changing data in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive and triple-negative BC, with also a hint to BRCA-related tumors and the emerging HER2-low-positive category.
Identifiants
pubmed: 35227965
pii: S2059-7029(22)00030-8
doi: 10.1016/j.esmoop.2022.100409
pmc: PMC8886005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100409Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure GG reports personal fees from Eli Lilly and Novartis, outside the submitted work. MVD reports personal fees from Eli Lilly, Exact Sciences, Novartis, Pfizer, Seagen, outside the submitted work. VG reports personal fees from Novartis, Roche, Eli Lilly, MSD, outside the submitted work. The remaining authors declare no competing interests.
Références
Lancet Oncol. 2021 Mar;22(3):351-360
pubmed: 33581774
Cancer Res. 2008 Nov 15;68(22):9280-90
pubmed: 19010901
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1084-91
pubmed: 19336551
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Ann Oncol. 2021 Dec;32(12):1475-1495
pubmed: 34678411
Ann Oncol. 2016 Aug;27(8):1525-31
pubmed: 27177860
Lancet Oncol. 2018 Jul;19(7):880-888
pubmed: 29804905
J Clin Oncol. 2021 Apr 20;39(12):1360-1370
pubmed: 33513026
J Natl Cancer Inst. 2021 Mar 1;113(3):309-317
pubmed: 32940689
J Natl Cancer Inst. 2021 Aug 2;113(8):1005-1016
pubmed: 33523233
JAMA Oncol. 2020 Jan 01;6(1):116-124
pubmed: 31563959
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Breast Cancer Res Treat. 2012 Jun;133(3):1067-75
pubmed: 22415477
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Ann Oncol. 2021 Sep;32(9):1148-1156
pubmed: 34116144
Ther Adv Med Oncol. 2011 Nov;3(6):257-67
pubmed: 22084640
J Clin Oncol. 2010 Mar 1;28(7):1124-30
pubmed: 20124187
Mol Oncol. 2011 Aug;5(4):387-93
pubmed: 21821475
Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242
pubmed: 24919460
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Cancer Res Treat. 2019 Jan;51(1):43-52
pubmed: 29458237
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
Curr Med Res Opin. 2014 Jun;30(6):1007-16
pubmed: 24490834
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
J Clin Oncol. 2018 Oct 1;36(28):2826-2835
pubmed: 30106636
Cancer Sci. 2016 Jul;107(7):1039-46
pubmed: 27166974
J Clin Oncol. 2018 Mar 10;36(8):741-748
pubmed: 29244528
Clin Cancer Res. 2022 Feb 15;28(4):637-645
pubmed: 34810217
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108
pubmed: 27026201
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
Eur J Cancer. 2018 May;95:93-101
pubmed: 29655061
Lancet Oncol. 2014 Jun;15(7):689-99
pubmed: 24793816
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
ESMO Open. 2020 Nov;5(6):e001112
pubmed: 33214229
Ther Adv Med Oncol. 2018 Sep 03;10:1758835918793326
pubmed: 30202447
Ann Oncol. 2014 Dec;25(12):2357-2362
pubmed: 25231953
Cancers (Basel). 2020 Jul 14;12(7):
pubmed: 32674482
J Clin Oncol. 2020 Aug 10;38(23):2610-2619
pubmed: 32468955
N Engl J Med. 2018 Nov 22;379(21):2052-2062
pubmed: 30462943
Eur J Cancer. 2016 Dec;69:216-222
pubmed: 27847222
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224
pubmed: 28533223
Cancer Discov. 2011 Sep;1(4):338-51
pubmed: 22049316
Oncologist. 2014 Jun;19(6):608-15
pubmed: 24794159
Lancet Oncol. 2021 Apr;22(4):489-498
pubmed: 33794206
J Clin Oncol. 2018 Sep 10;36(26):2736-2740
pubmed: 29939838
Lancet Oncol. 2017 Jun;18(6):743-754
pubmed: 28526538
Ann Oncol. 2016 Feb;27(2):256-62
pubmed: 26578730
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Lancet Oncol. 2021 Aug;22(8):1051-1052
pubmed: 34252373
J Clin Oncol. 2015 May 10;33(14):1564-73
pubmed: 25605838
Invest New Drugs. 2014 Oct;32(5):825-37
pubmed: 24919854
Ann Oncol. 2020 Nov;31(11):1526-1535
pubmed: 32828825
Breast Cancer Res Treat. 2019 Apr;174(3):719-729
pubmed: 30632023
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
Breast Cancer Res Treat. 2017 Feb;161(3):549-556
pubmed: 28000014
Breast Cancer (Dove Med Press). 2021 Feb 25;13:151-159
pubmed: 33658846
Clin Breast Cancer. 2020 Jun;20(3):e232-e243
pubmed: 32234362
Ann Oncol. 2021 Aug;32(8):983-993
pubmed: 34272041
JAMA Oncol. 2021 Apr 01;7(4):573-584
pubmed: 33480963
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
Breast Cancer Res Treat. 2010 Jun;121(2):261-71
pubmed: 20229176
N Engl J Med. 2020 Feb 6;382(6):514-524
pubmed: 31826360
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Oncologist. 2010;15(9):924-34
pubmed: 20736298
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Lancet Oncol. 2017 Jun;18(6):732-742
pubmed: 28526536
N Engl J Med. 2015 Jul 16;373(3):209-19
pubmed: 26030518
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Ann Oncol. 2021 Aug;32(8):994-1004
pubmed: 34219000
Sci Transl Med. 2015 Apr 15;7(283):283ra51
pubmed: 25877889
Clin Cancer Res. 2017 Aug 15;23(16):4793-4804
pubmed: 28473534
Ann Oncol. 2021 Apr;32(4):488-499
pubmed: 33385521
Oncotarget. 2015 Sep 8;6(26):22496-512
pubmed: 26101915
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
Ann Oncol. 2019 Apr 1;30(4):558-566
pubmed: 30689707
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Nat Genet. 2013 Dec;45(12):1415-6
pubmed: 24270445
Cancers (Basel). 2020 Nov 10;12(11):
pubmed: 33182657
J Clin Pharmacol. 2017 Feb;57(2):173-184
pubmed: 27402157
J Clin Oncol. 2021 Dec 10;39(35):3959-3977
pubmed: 34324367
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Ann Oncol. 2017 Oct 01;28(10):2340-2366
pubmed: 28945867
Oncologist. 2009 Apr;14(4):320-68
pubmed: 19346299
Lancet Oncol. 2018 Jan;19(1):87-100
pubmed: 29223745
Lancet Oncol. 2020 Oct;21(10):1296-1308
pubmed: 32919527
Oncologist. 2009 Jul;14(7):645-56
pubmed: 19608638
Oncotarget. 2017 May 10;8(41):69493-69507
pubmed: 29050219
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
Eur J Cancer. 2021 Sep;154:21-29
pubmed: 34225066
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
Oncologist. 2019 Nov;24(11):e1055-e1069
pubmed: 31444294
Breast Cancer Res. 2016 Feb 09;18(1):17
pubmed: 26857361
Cancer Res. 2006 Aug 15;66(16):8297-308
pubmed: 16912212
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Mol Cancer Ther. 2014 Nov;13(11):2618-29
pubmed: 25189543
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
J Clin Oncol. 2020 Sep 20;38(27):3138-3149
pubmed: 32678716